XBIT - XBiotech says its antibody therapy is effective against new COVID-19 strain

After an analysis against mutant COVID-19 virus found in the U.K., XBiotech ([[XBIT]] +4.6%) says its COVID-19 candidate True Human™ antibody therapy may also be used for treating the new coronavirus strain.XBiotech’s candidate that specifically targets the so-called spike protein was found to have the same high affinity for spike protein of both the original COVID-19 and mutant COVID-19 viruses the company said, citing a test that evaluated its ability to bind the spike protein of the new strain.The CDC has projected that the new variant will be the main cause of COVID infections in the USA by March if adequate precautions were not taken.XBiotech announced in November that its candidate True Human™ therapy could neutralize the virus at concentrations about four-times better than antibodies against COVID-19 approved by the FDA under emergency use authorization.

For further details see:

XBiotech says its antibody therapy is effective against new COVID-19 strain